CK Life Sciences International Holdings (STU:LSI) 3-Year EBITDA Growth Rate : 9.90% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is CK Life Sciences International Holdings 3-Year EBITDA Growth Rate?

CK Life Sciences International Holdings's EBITDA per Share for the six months ended in Dec. 2023 was €0.00.

During the past 12 months, CK Life Sciences International Holdings's average EBITDA Per Share Growth Rate was 4.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 9.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -0.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 0.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of CK Life Sciences International Holdings was 97.20% per year. The lowest was -17.80% per year. And the median was 9.90% per year.

Competitive Comparison of CK Life Sciences International Holdings's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, CK Life Sciences International Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CK Life Sciences International Holdings's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CK Life Sciences International Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where CK Life Sciences International Holdings's 3-Year EBITDA Growth Rate falls into.

CK Life Sciences International Holdings 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

CK Life Sciences International Holdings (STU:LSI) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

CK Life Sciences International Holdings 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of CK Life Sciences International Holdings's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CK Life Sciences International Holdings (STU:LSI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CK Life Sciences International Holdings Inc (STU:LSI) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

00775:Hong Kong

Address

2 Dai Fu Street, Tai Po Industrial Estate, Tai Po, Hong Kong, HKG

Website

https://www.ck-lifesciences.com

CK Life Sciences International Holdings Inc is a biotechnology company engaged in the research & development, commercialization, and sale of health and agricultural-related products. Products developed by CK Life Sciences are categorized into the areas of human health and environmental sustainability. The company operates three core businesses, including agriculture, nutraceutical, and pharmaceutical. Its overall product portfolio involves a presence that spans North America and the Asia Pacific. The company uses mergers and acquisitions when it identifies attractive market opportunities.